ArticleBMJ public health2025
Burden of disease attributable to high body mass index in Belgium: a comparative risk assessment analysis.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer.Annals of medicine · 2025Article
- Prevalence and associated factors of overweight, obesity, and central obesity among adults in Northern Sudan: a community-based cross-sectional study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and methods: High body mass index (BMI) is a major risk factor for several non-communicable diseases. The increasing concern about the health and economic burden of BMI makes it essential for countries to track their progress on major modifiable risk exposures. The aim of the study is to estimate the burden attributable to high BMI in Belgium, in terms of years of life lost due to disability (YLD), years of life lost due to premature mortality (YLL) and disease costs, using comparative risk assessment. We followed the general framework established in the Global Burden of Diseases, Injuries and Risk Factors study. Population attributable fractions were calculated for the year 2018 for selected health outcomes using local estimates of BMI and burden of disease estimates from the Belgian Burden of Disease study. Results: According to our figures, around 37 800 YLD, 56 000 YLL and €1.85 billion in healthcare costs can be attributed to a high BMI. Diabetes had the highest number of YLD attributable to high BMI followed by musculoskeletal disorders. Cardiovascular diseases accounted for the highest burden in terms of YLL attributable to high BMI, followed by diabetes and different forms of cancers (i.e., breast, colon and rectum and oesophageal cancer). Conclusion: A substantial proportion of the burden of disease could be prevented when reducing BMI in Belgium. This evidence on the impact of risk factors is important for monitoring disease burdens and setting priorities for health prevention policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.